Update: Lonza Acquires Genentech Biologics Manufacturing Site in Vacaville

Lonza acquires Genentech’s Vacaville biologics site from Roche for $1.2 billion, expanding large-scale manufacturing capacity in the US, investing $500 million for upgrades.